Browse treatments

…se to immune checkpoint blockade (ICB) cancer immunotherapy and adoptive T cell therapy,1 2 but the identity of the subpopulations of TIL critical for …

…ts that limit the efficacy of immune checkpoint blockade (ICB). Adoptive TIL therapy may overcome this limitation, but its success depends on robust…

…Background Adoptive cell therapy using tumor infiltrating lymphocytes (TIL) is approved for trea…

…Background Tumor Infiltrating Lymphocyte (TIL) therapy is an autologous treatment for solid tumors involving isolation…

…Background Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown promising…

…Background While chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies, i…

…Background Chimeric antigen receptor (CAR) T cell therapy has revolutionized treatment for hematologic malignancies, but …

…and durable responses against many solid tumors remain lacking. CAR T cell therapy is promising but is hindered by a lack of tumor-specific target…

…ical role in tumor initiation and progression. In recent years, T cell-based therapies have emerged as one of the most promising approaches of cancer …

…Background Immune checkpoint inhibitors targeting PD-1/PD-L1 have been approved over the last decade fo…

… therapy, 18.5% received combination therapy, and 5.0% received anti-CTLA4 therapy. Patients with an iatrogenic etiology experienced significantly…

…stics of patients, allowing for more personalized and effective immunotherapies. Immunohistochemistry (IHC) is the gold-standard technique for …